+44 7723 059341
Emerging biotechs now own two-thirds of the drug pipeline – double their 2002 share – yet few have a senior CMC lead in-house.1 Z2 gives start-ups experienced cell line, upstream and CMC leadership when they need it, without a permanent hire.
67%
of the global R&D pipeline held by emerging biopharma in 20221
18 months
typical CMC work to reach IND for a monoclonal antibody, costing about $7M2
36%
of biomanufacturing facilities cannot hire process development staff3
How Z2 helps
- A CMC lead without a permanent hire
- Cell line development and CDMO choice set up right
- Clone-selection, stability and clonality criteria agreed before the CDMO starts
- Upstream development, scale-up and technology-transfer planning
- A CMC plan, budget and risk register investors can check line by line
- Scientific input to grants, funding proposals and investor decks
Incubators & accelerators
For life-science incubators and accelerators, Z2 supports laboratory set-up for resident start-ups and provides CMC mentoring for cohorts.
Where rushed timelines break
Speed-first CDMO packages that save months but leave the clone unproven; budgets with no line for tech transfer or rework.
Where Z2 helps
Senior judgement at the decisions that matter – host, clone, CDMO and CMC plan – before they become expensive.
Sources
- IQVIA Institute. Global Trends in R&D 2023. Emerging biopharma: R&D spend under $200M and sales under $500M a year.
- Contract Pharma. CMC Activities for Development of MAbs, updated September 2024.
- BioPlan Associates. 22nd Annual Report and Survey of Biopharmaceutical Manufacturing, April 2025.
